Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study

Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study

Abstract Background In the EDITA trial, patients with systemic sclerosis (SSc) and mild pulmonary vascular disease (PVD) treated with ambrisentan had a significant decline of pulmonary vascular resistance (PVR) but not of mean pulmonary arterial pressure (mPAP) vs. placebo after six months. The EDIT...

Full description

Bibliographic Details
Main Authors: Panagiota Xanthouli, Paul Uesbeck, Hanns-Martin Lorenz, Norbert Blank, Christina A. Eichstaedt, Satenik Harutyunova, Benjamin Egenlauf, Jerry G. Coghlan, Christopher P. Denton, Ekkehard Grünig, Nicola Benjamin
Format: Article
Language:English
Published: BMC 2024-07-01
Series:Arthritis Research & Therapy
Subjects:
Early treatment
Ambrisentan
Systemic sclerosis
Pulmonary vascular disease
Online Access:https://doi.org/10.1186/s13075-024-03363-0

Internet

https://doi.org/10.1186/s13075-024-03363-0

Similar Items